论文部分内容阅读
目的观察雷贝拉唑对消化性溃疡相关症状的改善程度及其安全性。方法在浙江省13家医院进行多中心、开放试验。观察对象:经胃镜诊断为消化性溃疡,有上腹痛、反酸和上腹烧灼感等症状的患者。服用雷贝拉唑片(波利特)10mg,每晨服一次,共5d;记录用药前1天及用药后第1、2、5天的症状并评分,同时记录出现的不良反应。结果本试验共入选消化性溃疡患者1159例。第1、2、5天患者总体症状缓解率分别为67.5%、98.3%、99.7%;而总体症状消失率分别为23.3%、51.8%、83.6%。第2、5天的缓解率及消失率分别与第1天相比差异均有统计学意义(均P<0.01)。结论雷贝拉唑能快速有效的缓解消化性溃疡患者的症状,安全性好。
Objective To observe the improvement and safety of rabeprazole on peptic ulcer-related symptoms. Methods In 13 hospitals in Zhejiang Province, a multicenter and open trial was conducted. Observed: Gastroscopy diagnosis of peptic ulcer, abdominal pain, acid reflux and abdominal burning sensation and other symptoms of patients. Take rabeprazole tablets (Polite) 10mg, every morning service, a total of 5d; record the day before treatment and 1, 2, 5 days after treatment symptoms and scores, and record the adverse reactions. Results A total of 1159 patients with peptic ulcer were enrolled in this study. The overall symptom relief rates of patients on the 1st, 2nd and 5th days were 67.5%, 98.3% and 99.7% respectively, while the disappearance rates of the total symptoms were 23.3%, 51.8% and 83.6% respectively. The rates of remission and disappearance on day 2 and day 5 were significantly different from those on day 1 (all P <0.01). Conclusion Rabeprazole can quickly and effectively relieve the symptoms of patients with peptic ulcer and has good safety.